Over Prescribing Proton Pump Inhibitors & a Glimpse on Its Side Effects

Mohammed Abubakar, Sidra Fatima and Aleena Mahvash
Additional contact information
Mohammed Abubakar: Department of Internal Medicine, Owaisi Hospital & Research Centre, India
Sidra Fatima: Gandhi Medical College, India
Aleena Mahvash: Deccan College of Medical Sciences, India

Novel Approaches in Drug Designing & Development, 2017, vol. 2, issue 3, 47-49

Abstract: Proton pump inhibitors are one of the most frequently prescribed classes of drug in the world because they combine a high level of efficacy with low toxicity. In 2006, expenditure on these drugs was £7bn globally [1] Yet studies consistently show that proton pump inhibitors are being overprescribed worldwide in both primary and secondary care [2]. Between 25% and 70% of patients taking these drugs have no appropriate indication. This means that, at the very least, £100m from the National Health Service (NHS) budget and almost £2bn worldwide is being spent unnecessarily on proton pump inhibitors each year.

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555587.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555587.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:2:y:2017:i:3:p:47-49

DOI: 10.19080/NAPDD.2017.02.555587

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().